Home/Filings/4/0001209191-19-002201
4//SEC Filing

Ryali Sriram 4

Accession 0001209191-19-002201

CIK 0001305253other

Filed

Jan 3, 7:00 PM ET

Accepted

Jan 4, 5:51 PM ET

Size

5.5 KB

Accession

0001209191-19-002201

Insider Transaction Report

Form 4
Period: 2019-01-03
Ryali Sriram
Chief Financial Officer
Transactions
  • Award

    Stock Option ( Right to Buy)

    2019-01-03+90,00090,000 total
    Exercise: $10.46Exp: 2029-01-02Common Stock (90,000 underlying)
Footnotes (1)
  • [F1]The option will vest as to 25% of the option shares on December 17, 2019 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.

Issuer

Eiger BioPharmaceuticals, Inc.

CIK 0001305253

Entity typeother

Related Parties

1
  • filerCIK 0001762893

Filing Metadata

Form type
4
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 5:51 PM ET
Size
5.5 KB